No mention of Firefly or Novadaq. However, nearly the first comments from Gary were about procedure growth areas. He highlighted two, hernia repair and colorectal resection. The latter benefits Novadaq greatly.
So, what happened two months ago? - Horrible Q1 results were released with an EPS surprise of -122%; a powerful incentive to short. As a result share price dropped hard but is now right back to where it was before the release, even in the face of continued heavy shorting. On the other side of every short bet, someone called and raised.
However, given the overoptimistic slant of management over the past year, I suspect the next quarter sales will hit GSA's inconclusive range and the share price will bounce around for another quarter.
Realistically, even if the repeal clears the house and senate, do you believe Mr. Obama would sign it? As it stands, the Affordable Care Act is his central legacy piece. Even a modest change would likely be seen by him as an unraveling thread.
Yes. And you forgot to mention the 19th century mustache over the "o". Probably an html hiccup (or maybe headquarters is moving to SE Asia).
If the lack of price movement of MDT, JNJ, SYK, and ISRG is an indicator, the repeal of the medical device tax is probably not reason for the jump. I vote for positive channel checks.
Available from sec.gov - NVDQ - Form 13G. Also search terms from headline, Why Primecap Management Co Just Disclosed Huge New Novadaq Technologies Inc Stake.
According to the conference calls, as of October 1, 2014 Novadaq had 41 sales professionals and 6 clinical specialists, by the end of of that year this had gone to 75 sales professionals and 25 clinical specialists.
By March 31, 2015 this had grown to 78 sales professionals and 29 clinical specialists.
Being a Canadian company, Novadaq's financial reporting isn't always available from the usual outlets. However, I'm seeing some insider buys from both Dr. Arun Menawat (~15,000 shares, May 4 and 11) and Roger Deck (40,000 shares, May 1). Nice to see them stepping up!
Agreed, he was very positive and reaffirmed 2015 revenue guidance. Did you catch that compared to last year's slide on targeted SPY procedures, the total has risen from 1.7 million to 2.0 million? The difference lies with splitting out lymphatic into its own category with 400,000 procedures and dropping gynecology back from 200,000 to 100,000.
At the end of April, in the investors section of their website, Novadaq released a new letter from Arun. It discusses events of the last couple of years, studies (completed and in progress), partners, patents (89 granted and 102 pending), and the direction of the company's future efforts.